In recent years, concern has been growing that traditional research and development models in the life sciences are unsustainable. Productivity, especially in pharmaceuticals, has plummeted, and too many of the products emerging from increasingly lengthy and costly clinical development offer marginal benefit to patients. Although the phenomenon is global, there are specific and important features of European life sciences that impede the translation of an ever more penetrating understanding of biology into effective treatments. This article analyzes these issues in the context of European biopharmaceutical innovation, describes the actions that Europe is already taking, and suggests what more needs to be done.
Keywords: Eroom's Law; drug development; drug discovery; technology transfer; translational medicine.